Recommendation of the President – Jemperli (dostarlimab)
On 21 October 2024, the President of the Agency for Health Technology Assessment and Tariff System issued recommendation No. 112/2024 on the evaluation of the drug Jemperli (dostarlimab) under the drug program “Treatment of patients with endometrial cancer (ICD-10 C54)”